TSCAN THERAPEUTICS, INC. (TCRX) Total liabilities 2020–2025
TSCAN THERAPEUTICS, INC. (TCRX) total liabilities at each fiscal year-end, per SEC filings.
$105.7MFY2025 · since FY2020: $32.5M → $105.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $105.7M | -18.8% |
| FY2024 | $130.1M | +7.3% |
| FY2023 | $121.3M | +21.7% |
| FY2022 | $99.7M | +264.7% |
| FY2021 | $27.3M | -16.0% |
| FY2020 | $32.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRX financial trends
TCRX RevenueTCRX Net incomeTCRX Net marginTCRX Gross profitTCRX Gross marginTCRX Operating incomeTCRX Operating marginTCRX Operating cash flowTCRX Free cash flowTCRX Capital expendituresTCRX Return on equityTCRX Stock buybacksTCRX Dividends paidTCRX Total assetsTCRX Shareholders’ equityTCRX overview →